{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:46:35Z","timestamp":1761947195580},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2003,11,19]],"date-time":"2003-11-19T00:00:00Z","timestamp":1069200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> The German Multicentre acute lymphoblastic leukaemia (ALL) study group (GMALL) performed a pilot study using pegylated asparaginase (PEG\u2010ASP) in combination with high\u2010dose methotrexate as consolidation therapy in the 05\/93 protocol. The aim of the study was an intra\u2010individual comparison of two different doses of PEG\u2010ASP in 26 patients, with regard to the depletion of asparagine in serum and toxicity. \u2018Pharmacokinetic\u2019 monitoring was performed to evaluate the effect of an intra\u2010individual dose escalation of PEG\u2010ASP from 500 to 1000\u2003U\/m<jats:sup>2<\/jats:sup> intravenously in successive doses. Serum asparaginase activity was targeted at \u2265100\u2003U\/l for 1\u2003week and \u226550\u2003U\/l for 10\u2003d. The second course of PEG\u2010ASP was administered to 23 patients. Due to hypersensitivity reactions in five patients, only 18 patients were evaluable for pharmacokinetic monitoring. With respect to the PEG\u2010ASP activity, an effective depletion of asparagine could be postulated in the majority of patients during 10\u2003d after the first administration. The effect of an intraindividual dose escalation form 500 to 1000\u2003U\/m<jats:sup>2<\/jats:sup> was evaluable in 17 of 22 patients. An increment in peak PEG\u2010ASP activity &gt;70% was observed in 65% of the patients. PEG\u2010ASP was well tolerated. Despite the long half\u2010life of PEG\u2010ASP, neither pancreatic nor central nervous toxicities occurred among the 26 adult patients treated in this pilot study.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2003.04707.x","type":"journal-article","created":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T20:31:14Z","timestamp":1069360274000},"page":"836-841","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Pegylated asparaginase in combination with high\u2010dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study"],"prefix":"10.1111","volume":"123","author":[{"given":"O.","family":"Rosen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"G\u00f6kbuget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Peter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"H\u00e4hling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. H.","family":"Ittel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"M\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rothmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Boos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hoelzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the GMALL Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,11,19]]},"reference":[{"key":"e_1_2_19_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.5.1709"},{"key":"e_1_2_19_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.9.1780"},{"key":"e_1_2_19_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686177"},{"key":"e_1_2_19_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00131-1"},{"key":"e_1_2_19_6_1","first-page":"37","article-title":"Improvement in the therapeutic index of methotrexate (NSC 109229) by Lasparaginase (NSC 109299)","volume":"6","author":"Capizzi R.L.","year":"1975","journal-title":"Cancer Chemotherapy Reports"},{"key":"e_1_2_19_7_1","first-page":"115","article-title":"Asparaginase\u2010methotrexate in combination chemotherapy: Schedule\u2010dependent differential effects on normal versus neoplastic cells","volume":"65","author":"Capizzi R.L.","year":"1981","journal-title":"Cancer Treatment Reports"},{"key":"e_1_2_19_8_1","first-page":"1","volume-title":"Enzymes as Drugs","author":"Capizzi R.L.","year":"1981"},{"key":"e_1_2_19_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197610)38:4<1843::AID-CNCR2820380463>3.0.CO;2-J"},{"key":"e_1_2_19_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820401)49:7<1378::AID-CNCR2820490713>3.0.CO;2-Z"},{"issue":"1","key":"e_1_2_19_11_1","first-page":"669","article-title":"Toxicity and pharmacokinetics of PEG\u2010asparaginase (PEG\u2010asp) in newly diagnosed adult acute lymphoblastic leukemia (ALL): CALGB9511","volume":"88","author":"Frankel S.R.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_19_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19801101)46:9<2004::AID-CNCR2820460918>3.0.CO;2-S"},{"key":"e_1_2_19_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900615)65:12<2615::AID-CNCR2820651202>3.0.CO;2-X"},{"key":"e_1_2_19_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1989.tb01464.x"},{"key":"e_1_2_19_15_1","first-page":"304","article-title":"Antibodies to asparaginase alter pharmacokinetics and decreases enzyme activity in patients on asparaginase therapy","volume":"34","author":"Kurtzberg J.","year":"1993","journal-title":"Proceedings of the American Association for Cancer Research"},{"key":"e_1_2_19_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-2697(02)00232-4"},{"key":"e_1_2_19_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401007"},{"key":"e_1_2_19_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197903)43:3<1089::AID-CNCR2820430346>3.0.CO;2-H"},{"key":"e_1_2_19_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02187.x"},{"issue":"1","key":"e_1_2_19_20_1","first-page":"669","article-title":"The importance of L\u2010asparaginase (A\u2018ASE) in the treatment of of acute lymphoblastic leukemia (ALL) in children: results of the EORTC 58881 randomized phase III trial showing greater efficiency of Escherichia coli of (E. coli) as compared with Erwinia (ERW) A'ASE","volume":"88","author":"Otten J.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_19_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.2.355.355"},{"key":"e_1_2_19_22_1","first-page":"4554","article-title":"L\u2010asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans","volume":"41","author":"Riccardi R.","year":"1981","journal-title":"Cancer Research"},{"key":"e_1_2_19_23_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008368916800"},{"key":"e_1_2_19_24_1","first-page":"2014","article-title":"Schedule\u2010dependent therapeutic synergism for L\u2010asparaginase and methotrexate in leukemic (L5178Y) mice","volume":"33","author":"Vadlamudi S.","year":"1973","journal-title":"Cancer Research"},{"key":"e_1_2_19_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01192.x"},{"key":"e_1_2_19_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.5.827"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2003.04707.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2003.04707.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2003.04707.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T20:06:54Z","timestamp":1697400414000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2003.04707.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,19]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1046\/j.1365-2141.2003.04707.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04707.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2003,11,19]]},"assertion":[{"value":"2003-11-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}